AlzeCure Pharma

ALZCUR · Nasdaq Stockholm · Healthcare

6.86SEK −5.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: +165.9%

Performance

1 month

−15.7%

1 year

+165.9%

3 years, per year

+21.5%

5 years, per year

−0.5%

Largest fall, 3 years

−84.6%

Below the peak now

−34.7%

Volatility, 1 year

262.2%

Return with dividends reinvested.

Key figures

P/E

29.7

P/B

10.0

Dividend yield

0.0%

Return on equity

+33.6%

Net margin

+31.6%

Market value

94 m USD

Quality, value and trend

Where AlzeCure Pharma stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value12

The price measured against earnings, assets and cash flow. Better than 12% of Nordic stocks.

Trend89

The price development over the past year. Better than 89% of Nordic stocks.

Combined81

Quality, value and trend together. Better than 81% of Nordic stocks.

About AlzeCure Pharma

AlzeCure Pharma is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pa…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis